Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
Running, not enrolling · Phase 3
Conditions studied: Advanced or Metastatic Breast Cancer
In brief
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.
Key facts
- Study ID
- NCT04494425
- Run by
- AstraZeneca
- People needed
- 866
- Starts
- 2020-07-24
- Expected to finish
- 2026-06-19
- Last updated by the study team
- 2026-03-04
Who can join
Age: 18 and older, up to 105. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — New Delhi, India
- Research Site — New Delhi, India
- Research Site — Surat, India
- Research Site — Thiruvananthapuram, India
- Research Site — Haifa, Israel
- Research Site — Jerusalem, Israel
- Research Site — Jerusalem, Israel
- Research Site — Kfar Saba, Israel
- Research Site — Petah Tikva, Israel
- Research Site — Ramat Gan, Israel
- Research Site — Tel Aviv, Israel
- Research Site — Aviano, Italy
- Research Site — Bergamo, Italy
- Research Site — Candiolo, Italy
- Research Site — Cona, Italy
- Research Site — Genova, Italy
- Research Site — Livorno, Italy
- Research Site — Messina, Italy
- Research Site — Milan, Italy
- Research Site — Milan, Italy
- Research Site — Naples, Italy
- Research Site — Padova, Italy
- Research Site — Parma, Italy
- Research Site — Prato, Italy
- Research Site — New Delhi, India
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.